An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: Utility for Fabry disease diagnosis and treatment monitoring

Clinica Chimica Acta

Volumn 403, Issue 1-2, 2009, Pages 194-197

  Rozenfeld, Paula A ^a   De Francesco, Nicolas P ^a   Borrajo, Gustavo J C ^b   Ceci, Romina ^a   Fossati, Carlos A ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Fundacion Bioquimica   (Argentina)

Author keywords

Diagnosis; Enzyme replacement therapy; Fabry disease; Globotriaosylceramide; Lysosomal storage disorders; Urinary sediment

Indexed keywords

AGALSIDASE ALFA; GALACTOSE; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLCERAMIDE GB3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEMIZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; URINARY EXCRETION; URINE SEDIMENT;

ADULT; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FABRY DISEASE; FEMALE; HUMANS; LINEAR MODELS; MALE; SENSITIVITY AND SPECIFICITY; TRIHEXOSYLCERAMIDES;

EID: 64849106446     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.02.016     Document Type: Article

References (23)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., and Laster L. Enzymatic defect in Fabry disease. Ceramidetrihexoside deficiency. N Engl J Med 276 (1967) 1163-1167
2. Kint J.A. Fabry disease. Alpha galactosidase deficiency. Science 167 (1970) 1268-1269
3. Desnick R.J., Ioannou Y.A., Eng C.M., α-galactosidase A deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.X., Valle D., eds; Childs B., Kinzler K.W., Vogelstein B., assoc eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill, 2001: 3733-3774.
4. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38 (2001) 750-760
5. Whybra C., Kampmann C., and Willers I. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24 (2001) 715-724
6. Desnick R.J., Allen Y.K., Desnick S., Raman M.K., Bernlohr R.W., and Krivit W. Fabry's disease: enzymatic diagnosis of hemyzigotes and heterozygotes. α-Galactosidase A activities in plasma, serum, urine and leukocytes. J Lab Clin Med 81 (1973) 157-171
7. Garman S.C., and Garboczi D.N. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337 (2004) 319-335
8. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
9. Cable W.J., McCluer R.H., Kolodny E.H., and Ullman M.D. Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 32 (1982) 1139-1145
10. Whitfield P.D., Calvin J., Hogg S., O'Driscoll E., Halsall D., Burling K., et al. Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J Inherit Metab Dis 28 (2005) 21-33
11. Vance D.E., and Sweeley C.C. Quantitative determination of the neutral glycosyl ceramides in human blood. J Lipid Res 8 (1967) 621-630
12. Yamaguchi A., Fukushi M., Mizushima Y., Shimizu Y., Takasugi N., Arashima S., et al. Microassay for screening newborns for galactosemia with use of a fluorometric microplate. Clin Chem 35 (1989) 1962-1964
13. Eurachem Guide. "The Fitness for Purpose of Analytical Methods. A Laboratory Guide to Method Validation and Related Topics". First English Edition 1.0, 1998. (www.eurachem.org/guides/valid.pdf).
14. Young E., Mills K., Morris P., Vellodi A., Lee P., and Waldek S. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Paediatr Suppl 94 (2005) 51-54
15. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., et al. Elevated globotriaosilsphingosine is a hallmark of Fabry disease. PNAS 105 (2008) 2812-2817
16. Auray-Blais C., Cyr D., and Ntwari A. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 93 3 (2008) 331-340
17. Kitagawa T., Ishige N., Suzuki K., West M.L., Cox-Brinkman J., Bichet D.G., et al. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab 85 (2005) 196-202
18. Auray-Blais C., Cyr D., Mills K., Giguère R., and Drouin R. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J Inherit metab Dis 30 (2007) 106
19. Oshima M., Asano K., Shibata S., Suzuki Y., and Masuzawa M. Urinary neutral glycosphingolipid analysis of patients with Fabry's disease; rapid isocratic elution from high-performance liquid chromatography as per-o-benzoyl derivatives. Biochim Biophys Acta 1043 (1990) 157-160
20. Fuller M., Sharp P., and Rozaklis T. Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin Chem 51 (2005) 688-694
21. Vedder A.C., Linthorst G.E., van Breemen M.J., Groener J.E., Bemelman F.J., Strijland A., et al. The dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. JIMD 30 (2007) 68-78
22. Ohashi T., Sakuma M., Kitagawa T., Suzuki K., Ishige N., and Eto Y. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 92 (2007) 271-273
23. Vedder A.C., Breunig F., Donker-Koopman W.E., Mills K., Young E., Winchester B., et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94 (2008) 319-325